laninamivir: an antiviral agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 502272 |
| CHEMBL ID | 466246 |
| CHEBI ID | 177801 |
| SCHEMBL ID | 12284832 |
| MeSH ID | M0543369 |
| Synonym |
|---|
| CHEBI:177801 |
| (2r,3r,4s)-3-acetamido-4-(diaminomethylideneamino)-2-[(1r,2r)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid |
| laninamivir (cs-8958) |
| (2r,3r,4s)-3-acetamido-2-[(1r,2r)-2,3-dihydroxy-1-methoxy-propyl]-4-guanidino-3,4-dihydro-2h-pyran-6-carboxylic acid |
| 5-acetylamino-4-(diaminomethyl-amino)-6-(2,3-dihydroxy-1-methoxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid |
| laninamivir |
| r-125489 |
| 203120-17-6 |
| D09410 |
| laninamivir (inn) |
| 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-o-methyl-d-glycero-d-galacto-non-2-enonic acid |
| r 125489 |
| bdbm50009296 |
| CHEMBL466246 |
| A814430 |
| (4s,5r,6r)-5-acetamido-4-guanidino-6-((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid |
| b408iw3gl5 , |
| laninamivir [inn:jan] |
| (4s,5r,6r)-5-acetamido-4-carbamimidamido-6-((1r,2r)-3-hydroxy-2-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid |
| unii-b408iw3gl5 |
| BCP9000836 |
| BCPP000190 |
| AKOS015850995 |
| laninamivir [mart.] |
| laninamivir [who-dd] |
| laninamivir [mi] |
| laninamivir [inn] |
| SCHEMBL12284832 |
| (2r,3r,4s)-3-acetamido-2-((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-4-guanidino-3,4-dihydro-2h-pyran-6-carboxylic acid , |
| C21557 |
| d-glycero-d-galacto-non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-o-methyl- |
| lani |
| DB12791 |
| AKOS032947260 |
| DTXSID60942457 |
| EX-A4019 |
| BCP27633 |
| Q6487096 |
| CS-0003575 |
| MS-25321 |
| HY-14818 |
| r 125489r 125489 |
| GLXC-15033 |
| AC-36457 |
| (4s,5r,6r)-5-acetamido-4-guanidino-6- ((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid |
Laninamivir octanoate is a novel long-lasting NAI that has demonstrated in vitro activity against influenza A and B viruses. The prodrug is in phase II clinical trials in the United States and other countries.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Laninamivir octanoate is a recently developed inhaled neuraminidase inhibitor for treating influenza virus infection. " | ( A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. Fujii, T; Higashiguchi, M; Matsumoto, T, 2018) | 2.25 |
| "Laninamivir is a novel long-lasting NAI that has demonstrated in vitro activity against influenza A and B viruses, and its prodrug (laninamivir octanoate) is in phase II clinical trials in the United States and other countries." | ( Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. Abed, Y; Boivin, G; Desrochers, FM; Hamilton, S; Luttick, A; Pryor, MJ; Samson, M; Tucker, SP, 2014) | 1.34 |
| "Laninamivir is a 7-methoxy derivative of zanamivir, but a single dose is effective when taken as the laninamivir octanoate prodrug." | ( Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation. Barrett, S; McKimm-Breschkin, JL, 2015) | 1.39 |
| "Laninamivir is a long-acting antiviral requiring only a single dose for the treatment of influenza infection, making it an attractive alternative to existing neuraminidase inhibitors that require multiple doses over many days. " | ( Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection. Hurt, AC; Margo, K; Morton, DA; Mosse, J; Oh, DY; Panozzo, J; Piedrafita, D, 2015) | 2.12 |
| "Laninamivir octanoate is an inhaled drug with unique characteristics." | ( Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu, H; Kawai, N, 2011) | 2.53 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Laninamivir octanoate has displayed clinical efficacy comparable to that of oseltamivir and zanamivir against the H1N1 pandemic influenza strain from 2009, seasonal H3N2 influenza and influenza B viruses." | ( Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu, H; Kawai, N, 2011) | 2.53 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Adverse events of interest such as abnormal behavior/delirium, dizziness/vertigo, respiratory disorders, shock/syncope, and any other serious events were intensively reviewed by the Safety Evaluation Committee." | ( Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance. Eda, H; Fukushima, M; Nakano, T; Niwa, S; Okumura, A; Tanabe, T; Tsutsumi, H; Yonemochi, R, 2013) | 0.71 |
| " The aim of this study was to evaluate age-related clinical manifestations of adverse events (AEs) related to NAIs." | ( Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews. Han, N; Kim, IW; Oh, JM, 2020) | 0.56 |
CS-8958 disappeared from plasma with a half-life of about 2 hours. laninamivir was slowly eliminated from the body, lasting for even up to 144 hours after administration.
A single-center, open-label study was conducted to evaluate the plasma and intrapulmonary pharmacokinetics of laninamivir after a single nebulized administration of LO in healthy male Japanese subjects. The clinical and laboratory parameters and plasma and urinary concentrations of CS-8958 and laninmivir for 144 hours post dosing were measured.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The clinical and laboratory parameters and plasma and urinary concentrations of CS-8958 and laninamivir for 144 hours post dosing were measured." | ( Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. Ishizuka, H; Okabe, H; Yoshiba, S; Yoshihara, K, 2010) | 0.87 |
| " A single-center, open-label study was conducted to evaluate the plasma and intrapulmonary pharmacokinetics (PK) of laninamivir after a single nebulized administration of LO in healthy male Japanese subjects for identifying a safe and effective dosage regimen for a nebulizer." | ( Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects. Furuie, H; Ishizuka, H; Toyama, K, 2018) | 0.97 |
| " Our analysis indicated that the signal of anaphylaxis may varies based on the main component or dosage form of each anti-influenza drug." | ( Association between anaphylaxis and anti-influenza drug use: An analysis of the Japanese Adverse Drug Event Report database. Horikomi, Y; Ishii, T; Ohyama, K; Tanaka, H, 2021) | 0.62 |
| Class | Description |
|---|---|
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | IC50 (µMol) | 0.0115 | 0.0000 | 0.5035 | 10.0000 | AID542945; AID542946; AID542947; AID542948; AID542949; AID542950; AID542951; AID542952; AID542953; AID542954; AID542955; AID542956; AID542957; AID542958; AID542959; AID542960; AID542961; AID542962; AID542963; AID542964; AID542965; AID542966; AID542967; AID542968; AID542969; AID542970; AID542971; AID542995; AID542996; AID542997; AID542998; AID542999; AID543000; AID543001; AID543002; AID543003; AID543004; AID543006; AID543007; AID543183; AID543184; AID543186; AID543187 |
| Neuraminidase | Influenza A virus (A/RI/5+/1957(H2N2)) | IC50 (µMol) | 3.1000 | 0.8000 | 1.7667 | 3.1000 | AID1129834 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID567610 | Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID543207 | Inhibition of Vibrio cholerae neuraminidase by spectrofluorometric analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID573458 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. |
| AID352031 | Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) sialidase | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID1212209 | Drug level in primary cultured BALB/c mouse airway epithelial cells treated with laninamivir octanoate at 50 uM measured up 60 to 90 mins by LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567612 | Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212192 | AUClast in BALB/cAnNCrlCrlj mouse plasma treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID573448 | Drug level in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered as [14C]labeled compound intranasally as single dose measured 120 hrs post dose | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. |
| AID542977 | Inhibition of Influenza B virus (B/Akita/9/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542955 | Inhibition of Influenza A virus (A/Yamagata/83/2006(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542967 | Inhibition of Influenza A virus (A/Yamagata/2/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542981 | Inhibition of Influenza B virus (B/Aichi/3/2006(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567607 | Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542948 | Inhibition of Influenza A virus (A/Shiga/1/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567590 | Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567715 | Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID352033 | Inhibition of Influenza A virus (A/Singapore/1/1957 (H2N2)) sialidase | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID542962 | Inhibition of Influenza A virus (A/New York/55/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567597 | Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567591 | Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID543188 | Ratio of IC50 for Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) neuraminidase N294S mutant to IC50 for Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542951 | Inhibition of Influenza A virus (A/Saitama/78/2003(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567600 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID573441 | Half life in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered as [14C]labeled compound intranasally as single dose | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. |
| AID352035 | Inhibition of Influenza A virus (A/Kitakyushu/159/93(H3N2)) sialidase | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID567601 | Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567615 | Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542979 | Inhibition of Influenza B virus (B/Yamagata/145/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567711 | Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567617 | Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212174 | Cmax in BALB/cAnNCrlCrlj mouse plasma at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567707 | Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542947 | Inhibition of Influenza A virus (A/New Caledonia/20/1999(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543185 | Ratio of IC50 for Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) neuraminidase E119V mutant to IC50 for Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542998 | Inhibition of Influenza A virus (A/duck/Alberta/60/1976(H12N5)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212165 | Drug uptake in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally measured at 24 hrs by LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID543208 | Inhibition of Clostridium perfringens neuraminidase by spectrofluorometric analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542975 | Inhibition of Influenza B virus (B/Shiga/17/2002(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542970 | Inhibition of Influenza A virus (A/Tokushima/1/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567603 | Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID543211 | Cytotoxicity against dog MDCK cells by MTT calorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1129833 | Inhibition of Influenza A virus (A/RI/5+/1957(H2N2)) recombinant neuraminidase using MUNANA as substrate at 100 uM after 30 mins | 2014 | Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7 | Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity. |
| AID567713 | Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1))virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212194 | Drug uptake in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally measured at 4 hrs by LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID543206 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) assessed as inhibition of viral replication by plaque reduction assay | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567703 | Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542995 | Inhibition of Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01)(H5H1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543190 | Inhibition of Influenza B virus (B/Yokohama/UT3318/2005)) neuraminidase N294S mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542976 | Inhibition of Influenza B virus (B/Yamagata/15/2002(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543183 | Inhibition of Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567609 | Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542950 | Inhibition of Influenza A virus (A/Yamagata/57/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567722 | Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212183 | Elimination half life in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567724 | Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542996 | Inhibition of Influenza A virus (A/duck/Hokkaido/84/2002(H5N3)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567705 | Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212173 | Elimination half life in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567614 | Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212195 | Drug uptake in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally measured at 4 hrs by LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567593 | Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212171 | Cmax in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567608 | Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567613 | Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212191 | AUClast in BALB/cAnNCrlCrlj mouse plasma at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID542997 | Inhibition of Influenza A virus (A/turkey/Ontario/6,118/1968(H8N4)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543192 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 69 ug/kg, itn administered 4 hrs pre-infection and at 4 hrs and 18 hrs post-infection up to 10 days | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543003 | Inhibition of Influenza A virus (A/Yokohama/67/2006(clone 1)(H1N1)) wild type neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567725 | Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542958 | Inhibition of Influenza A virus (A/Kitakyushu/159/1993(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543006 | Inhibition of Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542983 | Inhibition of Influenza B virus (B/Mie/1/1993(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542978 | Inhibition of Influenza B virus (B/Tokushima/1/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543187 | Inhibition of Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) neuraminidase N294S mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567716 | Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567599 | Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542980 | Inhibition of Influenza B virus (B/Yamagata/398/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543212 | Cytotoxicity against human MOLT4 cells by MTT calorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212184 | Elimination half life in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID542946 | Inhibition of Influenza A virus (A/Yamagata/32/1989(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567594 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212186 | Elimination half life in BALB/cAnNCrlCrlj mouse plasma treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID1212168 | Drug uptake in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally measured at 24 hrs by LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567710 | Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567618 | Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567589 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542968 | Inhibition of Influenza A virus (A/Saitama/80/2003(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1857995 | Inhibition of influenza virus neuraminidase | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Sialidase Inhibitors with Different Mechanisms. |
| AID567723 | Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542988 | Inhibition of Influenza B virus (B/Yamagata/87/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543186 | Inhibition of Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567616 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212170 | Cmax in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567714 | Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567721 | Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567719 | Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542989 | Inhibition of Influenza B virus (B/Aichi/186/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567605 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567727 | Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID352045 | Antiviral activity against Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01) (H5N1)) assessed viral plaque reduction | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID1212196 | Drug uptake in BALB/cAnNCrlCrlj mouse plasma at 0.5 umol/kg administered intranasally measured after 8 hrs by LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID352044 | Antiviral activity against Influenza B virus (B/Mie/1/93) assessed viral plaque reduction | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID542986 | Inhibition of Influenza B virus (B/Shizuoka/58/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542945 | Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567704 | Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212182 | Elimination half life in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID542960 | Inhibition of Influenza A virus (A/Wellington/1/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID352036 | Inhibition of Influenza B virus (B/Mie/1/93) sialidase | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID567595 | Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542987 | Inhibition of Influenza B virus (B/Yamagata/85/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212177 | Tmax in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567708 | Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID352043 | Antiviral activity against Influenza A virus (A/Kitakyushu/159/93(H3N2)) assessed viral plaque reduction | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID1212180 | Tmax in BALB/cAnNCrlCrlj mouse plasma at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID352032 | Inhibition of Influenza A virus (A/Yamagata/32/1989 (H1N1)) sialidase | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID542949 | Inhibition of Influenza A virus (A/Yamagata/3/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542990 | Inhibition of Influenza B virus (B/Saitama/01/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID352034 | Inhibition of Influenza A virus (A/Aichi/2/1968(H3N2)) sialidase | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID1212190 | AUClast in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID1212169 | Cmax in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567709 | Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID352041 | Antiviral activity against Influenza A virus (A/Singapore/1/1957 (H2N2)) assessed viral plaque reduction | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID352039 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed viral plaque reduction | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID352042 | Antiviral activity against Influenza A virus (A/Aichi/2/1968(H3N2)) assessed viral plaque reduction | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID542959 | Inhibition of Influenza A virus (A/Wyoming/03/2003(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542964 | Inhibition of Influenza A virus (A/Wisconsin/67/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212193 | Cmax in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally measured at 24 hrs | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID1212167 | Elimination half life in human treated with laninamivir octanoate administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID542973 | Inhibition of Influenza B virus (B/Malaysia/2506/2004(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212188 | AUClast in BALB/cAnNCrlCrlj mouse epithelial lining fluid treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567712 | Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID543193 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 69 ug/kg, itn administered 4 hrs pre-infection and at 4 hrs and 18 hrs post-infection up to 20 days | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543001 | Inhibition of Influenza A virus (A/duck/Ukraine/1/1963(H3N8)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542971 | Inhibition of Influenza A virus (A/Saitama/07/2006(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542982 | Inhibition of Influenza B virus (B/Saitama/01/2006(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543182 | Ratio of IC50 for Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) neuraminidase R292K mutant to IC50 for Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212163 | Lipophilicity, log D of the compound at pH 7.4 | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID542991 | Inhibition of Influenza B virus (B/Sapporo/29/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212187 | AUClast in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID352040 | Antiviral activity against Influenza A virus (A/Yamagata/32/1989 (H1N1)) assessed viral plaque reduction | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID567720 | Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID573277 | Cmax in BALB/cAnNCrlCrlj mouse lung assessed as compound concentration per gram of tissue at 0.5 umol/kg administered as [14C]labeled compound intranasally as single dose | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. |
| AID542969 | Inhibition of Influenza A virus (A/Osaka/56/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212181 | Tmax in BALB/cAnNCrlCrlj mouse plasma treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID1212172 | Cmax in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID542963 | Inhibition of Influenza A virus (A/Hiroshima/52/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543184 | Inhibition of Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) neuraminidase E119V mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212175 | Cmax in BALB/cAnNCrlCrlj mouse plasma treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID1212166 | Tmax in human treated with laninamivir octanoate at 40 mg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID543005 | Ratio of IC50 for Influenza A virus (A/Yokohama/67/2006(clone 11)(H1N1)) neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Yokohama/67/2006(clone 1)(H1N1)) wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543002 | Inhibition of Influenza A virus (A/duck/Memphis/546/1974(H11N9)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID352046 | Antiviral activity against Tamiflu-resistant influenza A virus (A/Yokohama/67/2006 (H1N1)) assessed viral plaque reduction | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID542999 | Inhibition of Influenza A virus (A/duck/England/1/1956(H11N6)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID525069 | Half life in mouse | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. |
| AID542993 | Inhibition of Influenza B virus (B/Yamagata/1/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567604 | Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567702 | Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme expressing wild type enzyme by NA-star substrate based chemi | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212162 | Drug level in primary cultured BALB/c mouse airway epithelial cells treated with laninamivir octanoate at 50 uM measured at 24 hrs by LC-MS/MS analysis | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID542954 | Inhibition of Influenza A virus (A/Aichi/169/2005(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542965 | Inhibition of Influenza A virus (A/Shiga/5/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543209 | Inhibition of Newcastle disease virus neuraminidase by spectrofluorometric analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542972 | Inhibition of Influenza B virus (B/Brisbane/32/2002(Victoria) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542985 | Inhibition of Influenza B virus (B/Shiga/31/2002(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212189 | AUClast in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID542956 | Inhibition of Influenza A virus (A/Singapore/1/1957(H2N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542953 | Inhibition of Influenza A virus (A/Okinawa/42/2004(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542984 | Inhibition of Influenza B virus (B/Shanghai/361/2002(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567611 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567592 | Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567718 | Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID352038 | Inhibition of Tamiflu-resistant Influenza A virus (A/Yokohama/67/2006 (H1N1)) sialidase | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID573278 | Tmax in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered as [14C]labeled compound intranasally as single dose | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. |
| AID567602 | Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID543210 | Cytotoxicity against human HeLa cells by MTT calorimetric assay | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212178 | Tmax in BALB/cAnNCrlCrlj mouse lung at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID567598 | Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567596 | Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567588 | Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542966 | Inhibition of Influenza A virus (A/Yamagata/1/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543007 | Inhibition of Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) neuraminidase R292K mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542992 | Inhibition of Influenza B virus (B/Tokushima/1/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542974 | Inhibition of Influenza B virus (B/Ohio/01/2005(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1212176 | Tmax in BALB/cAnNCrlCrlj mouse epithelial lining fluid at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID543000 | Inhibition of Influenza A virus (A/seal/Massachusetts/1/1980(H7N7)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567726 | Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542957 | Inhibition of Influenza A virus (A/Aichi/2/1968(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID542952 | Inhibition of Influenza A virus (A/Aichi/193/2004(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID352047 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected mouse assessed as mouse survival at 0.2 umol/kg dosed intranasally 4 hrs before and 4 hrs, 17 hrs after viral infection measured 20 days post infection | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID543189 | Inhibition of Influenza B virus (B/Yokohama/UT2203/2005)) neuraminidase N294S mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567587 | Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542994 | Inhibition of Influenza B virus (B/Yamagata/113/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567706 | Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567586 | Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1212179 | Tmax in BALB/cAnNCrlCrlj mouse lung treated with laninamivir octanoate at 0.5 umol/kg administered intranasally | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1 | Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. |
| AID352037 | Inhibition of Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01) (H5N1)) sialidase | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. |
| AID1692537 | Oral bioavailability in rat | 2020 | European journal of medicinal chemistry, Aug-15, Volume: 200 | Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor. |
| AID542961 | Inhibition of Influenza A virus (A/California/07/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567717 | Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567728 | Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID543004 | Inhibition of Influenza A virus (A/Yokohama/67/2006(clone 11)(H1N1)) neuraminidase H274Y mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1129834 | Inhibition of Influenza A virus (A/RI/5+/1957(H2N2)) recombinant neuraminidase using MUNANA as substrate after 30 mins | 2014 | Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7 | Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity. |
| AID567606 | Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (2.94) | 29.6817 |
| 2010's | 85 (83.33) | 24.3611 |
| 2020's | 14 (13.73) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (36.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 15 (14.56%) | 5.53% |
| Reviews | 13 (12.62%) | 6.00% |
| Case Studies | 4 (3.88%) | 4.05% |
| Observational | 3 (2.91%) | 0.25% |
| Other | 68 (66.02%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CS-8958 - A Phase I, Double-blind, Placebo-controlled, Ascending, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects. [NCT00995826] | Phase 1 | 16 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B [NCT02014649] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2013-11-30 | Terminated(stopped due to Study was terminated as per BARDA decision to terminate contract.) | ||
| ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA) [NCT05648448] | Phase 2 | 250 participants (Anticipated) | Interventional | 2023-02-22 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate in Adults With Chronic Asthma [NCT02022761] | Phase 1 | 32 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection [NCT01793883] | Phase 2 | 639 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||